HighCycle Study: Effect of Acetazolamide on Acute Mountain Sickness in Women Compared to Men

January 21, 2026 updated by: University of Zurich

HighCycle Study: Effect of Acetazolamide on Acute Mountain Sickness in Women Compared to Men: A Randomized, Placebo-Controlled, Double-Blind Parallel Trial

Millions of people travel to high altitude for work or leisure activities and are exposed to reduced inspiratory oxygen partial pressure and hypoxemia that may lead to altitude illness, among which the most common form is acute mountain sickness (AMS). The main AMS symptoms are headache, malaise, weakness, and fatigue. Prospective studies have shown that 20-60% of newcomers at 2500-4000m develop AMS requiring them to take medications, while, at very high altitudes, AMS may progress to high altitude cerebral oedema. Whether women are more susceptible to AMS remains insufficiently understood since no prospective study controlled for sex hormones, use of hormone contraception or assessed menstrual cycle phase (MCP) at altitude. Therefore, women remain underrepresented and poorly characterized in high altitude studies. In addition, the efficacy and safety of 250 mg/day acetazolamide, the standard recommendation for AMS prevention, has never been compared between sexes, although, women have presumably higher acetazolamide plasma concentration due to lower blood volume. Given the known dose-dependent preventive but also side effects of acetazolamide and equal proportion of women and men among mountain travellers, there is an urgent need to conclusively quantify the efficacy and safety of pre-ventive acetazolamide therapy against AMS in women compared to men.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

303

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Gorod Bishkek
      • Bishkek, Gorod Bishkek, Kyrgyzstan, 720040
        • National center for cardiology and internal medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy, non-smoking men and women, age 18-44 years, without any disease and need of regular medication (including oral contraceptives).
  • BMI >18 kg/m2 and <30 kg/m2
  • Born, raised and currently living at altitudes <1000 m
  • Written informed consent
  • Premenopausal women with an eumenorrheic cycle

Exclusion Criteria:

  • Other types of contraceptvies (contraceptives (hormonal intrauterine device, vaginal ring, subcutaneous injections or implants, among others)
  • Pregnancy or nursing
  • Anaemic (haemoglobin concentration <10g/dl)
  • Any altitude trip <4 weks before the study
  • Allergy to acetazolamide and other sulfonamides

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: WOMEN - ACETAZOLAMIDE oral capsule
Acetazolamide 250 mg/day (capsules @125 mg; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
Active Comparator: MEN - ACETAZOLAMIDE oral capsule
Acetazolamide 250 mg/day (capsules @125 mg; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
Placebo Comparator: WOMEN - PLACEBO oral capsule
Placebo (capsules identically looking as acetazolamide capsules; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
Placebo Comparator: MEN - PLACEBO oral capsule
Placebo (capsules identically looking as acetazolamide capsules; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Acute Mountain Sickness (AMS) Incidence, LLS 2018
Time Frame: Day 1 to 3 at 3600 m
Sex-related difference between acetazolamide and placebo group in the incidence of AMS. AMS incidence will be defined as a Lake Louise Questionnaire version 2018 score of ≥3.
Day 1 to 3 at 3600 m

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Acute Mountain Sickness (AMS) Incidence, LLS 1993
Time Frame: Day 1 to 3 at 3600 m
Sex-related difference between acetazolamide and placebo group in the incidence of AMS. AMS incidence will be defined as a Lake Louise Questionnaire version 1993 score of ≥3.
Day 1 to 3 at 3600 m
Acute Mountain Sickness (AMS) Severity, LLS 2018
Time Frame: Day 1 to 3 at 3600 m
Sex-related difference between acetazolamide and placebo group in the AMS severity assessed by the Lake Louise Questionnaire version 2018.
Day 1 to 3 at 3600 m
Acute Mountain Sickness (AMS) Severity, LLS 1993
Time Frame: Day 1 to 3 at 3600 m
Sex-related difference between acetazolamide and placebo group in the AMS severity assessed by the Lake Louise Questionnaire version 1993.
Day 1 to 3 at 3600 m
Drug-related side effects
Time Frame: Day 1 to 3 at 3600 m
Sex-related difference between acetazolamide and placebo group in the incidence and severity of medication side effects.
Day 1 to 3 at 3600 m
Arterial blood gases
Time Frame: Day 2 at 760 m and day 2 at 3600 m
Sex-related differences between acetazolamide and placebo group in the arterial blood gases (pH, PaO2, PaCO2, SaO2).
Day 2 at 760 m and day 2 at 3600 m
Acetazolamide plasma concentration
Time Frame: Day 2 at 3600 m
Sex-related differences between acetazolamide plasma concentration assessed by dried blood spots.
Day 2 at 3600 m
Hypoxic ventilatory response
Time Frame: Day 2 at 760 m
Sex-related difference in the hypoxic ventilatory response assessed under FiO2 of 0.115 and while cycling on a bicycle at 30% of predicted maximal work capacity.
Day 2 at 760 m
Perceived pain visualization
Time Frame: Day 1 to 3 at 3600 m
Sex-related differences between acetazolamide and placebo group on perceived pain sensations, visualized by the SMaRT tablet app
Day 1 to 3 at 3600 m

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Michael Furian, Prof. Dr., University of Zurich
  • Study Director: Talant Sooronbaev, Prof. Dr., National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 15, 2024

Primary Completion (Actual)

August 31, 2025

Study Completion (Actual)

August 31, 2025

Study Registration Dates

First Submitted

July 5, 2024

First Submitted That Met QC Criteria

July 11, 2024

First Posted (Actual)

July 12, 2024

Study Record Updates

Last Update Posted (Actual)

January 23, 2026

Last Update Submitted That Met QC Criteria

January 21, 2026

Last Verified

May 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe